Higher sequencing throughput, falling costs, and streamlined workflows are driving broader adoption in academia and hospitals, supported by investments in oncology research and AI-assisted data interpretation.

Regional analysis covers North America, Latin America, Europe, Asia, the Middle East & Africa, and Oceania, with country-level scopes for each region.

North America led the market in 2024 with about 41% of global revenue, driven by strong healthcare infrastructure, regulatory frameworks, and active cancer research collaborations.

Market is segmented by product type (WGS, exome, targeted panels) and by application (disease risk, oncology diagnostics, pharmacogenomics), with a regional analysis framework and a detailed contents outline.

Several FAQs note a CAGR around 20% from 2024–2032 and a market size near USD 22.2 billion, fueled by declining costs, AI-driven analysis, precision medicine uptake, and North America as a leading region; consumables remain the largest segment.

Additional FAQs stress growth from precision medicine and cancer research, with NGS as the dominant technology and a notable 15% CAGR anticipated for 2025–2032.

The market spans technologies like PCR and NGS to applications in major cancers, with products and services including assays, instruments, and software, and samples including tissue, liquid biopsy, and cytology.

Forecasts project continued growth as genomic data fuels precision healthcare, enabled by cloud, AI, and advanced bioinformatics that make sequencing faster and more cost-efficient.

Localised solutions in APAC markets are a key driver of the region’s faster growth.

End-use markets show laboratories holding around the majority share, underscoring the central role of lab-based genomic testing in oncology care.

Large-scale WGS accounted for most of the market in 2023, while small WGS is expected to grow rapidly due to microbial genomics and pathogen tracking.

The genomic sequencing market is accelerating as cloud-enabled bioinformatics pipelines, long-read and single-cell sequencing expand, with growing ties between diagnostic labs and AI firms and a rise in direct-to-consumer genetic testing and multi-omics integration.